EU Healthcare Professionals​

This is an international website for NERLYNX® dedicated to EU Healthcare professionals ​​(outside the UK and ROI).

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that: 

I am a Healthcare Professional in the EU (outside the UK and ROI) and I have read the information above​, the Legal Notice and the Privacy Policy

Patients / Non EU Healthcare Professionals

This is an international website for NERLYNX® dedicated to EU Healthcare Professionals (outside the UK and ROI)

I am a patient or a Healthcare Professional outside the EU.

https://www.pierre-fabre.com/en

 

You’ve come this far – don’t stop now. Take one more step for additional protection.

 

NERLYNX® is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.

Extended adjuvant treatment with NERLYNX®

reduces the risk of HER2+/HR+ breast cancer recurrence by 51% after 2 years*†‡

Efficacy

Learn about ExteNET

study design and study results.

 

Learn more

Safety

Learn about NERLYNX® common adverse events, diarrhoea management and other safety information.

Learn more

Dosing 

Learn about NERLYNX® recommended

dose and dose adjustments.

 

Learn more


*Recurrence is defined as an invasive disease event or death.

†NERLYNX® used as extended adjuvant therapy for 12 months following trastuzumab-based therapy completed less than a year ago.

‡At 2 years, in the HER2+/HR+ population subgroup, iDFS = 95.3% in NERLYNX® arm (N=670) versus 90.8% in placebo (N=664).